FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130992263> ?p ?o ?g. }

• W2130992263 endingPage "6283" @default.
• W2130992263 startingPage "6277" @default.
• W2130992263 abstract "Abstract Purpose: AEZS-108, formerly AN-152, is a cytotoxic hybrid molecule consisting of a luteinizing hormone-releasing hormone (LHRH) agonist moiety covalently coupled to doxorubicin, allowing it to deliver doxorubicin selectively to cells expressing LHRH receptors. LHRH receptors are expressed on the cell membrane of many tumors, including prostate cancer. This phase I study determined the maximum tolerated dose (MTD) of AEZS-108 in men with taxane- and castration-resistant prostate cancer (CRPC) while providing additional information on the safety profile and efficacy of this agent. Experimental Design: AEZS-108 was administered as an intravenous infusion every 21 days until progression or unacceptable toxicity in cohorts of 3 or 6 patients until the MTD was reached. Blood was collected for capture of circulating tumor cells (CTC) to visualize internalization of AEZS-108, an autofluorescent molecule. Results: The MTD of AEZS-108 in this cohort was 210 mg/m2, which was lower than that seen in a phase I study conducted in women with endometrial or ovarian cancers. The dose-limiting toxicity was persistent neutropenia. Three patients had a PSA response with an additional 10 patients maintaining PSA stable disease. Of the 10 patients evaluable by RECIST criteria, 9 achieved stable disease. AEZS-108 internalization in CTCs was routinely visualized using its autofluorescence. Conclusion: These findings show that AEZS-108 has an acceptable safety profile and a signal of efficacy, lowering PSA in heavily pretreated patients with prostate cancer, and that internalization of AEZS-108 in prostate cancer CTCs may be a viable pharmacodynamic marker. A phase II study in men with prostate cancer is ongoing. Clin Cancer Res; 20(24); 6277–83. ©2014 AACR." @default.
• W2130992263 created "2016-06-24" @default.
• W2130992263 creator A5009732369 @default.
• W2130992263 creator A5020334875 @default.
• W2130992263 creator A5026186298 @default.
• W2130992263 creator A5031088617 @default.
• W2130992263 creator A5043871151 @default.
• W2130992263 creator A5047212274 @default.
• W2130992263 creator A5062167990 @default.
• W2130992263 creator A5063861158 @default.
• W2130992263 creator A5067387322 @default.
• W2130992263 creator A5079064470 @default.
• W2130992263 creator A5091696839 @default.
• W2130992263 date "2014-12-14" @default.
• W2130992263 modified "2023-09-27" @default.
• W2130992263 title "Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer" @default.
• W2130992263 cites W1487152933 @default.
• W2130992263 cites W1540792390 @default.
• W2130992263 cites W1776913920 @default.
• W2130992263 cites W1967234155 @default.
• W2130992263 cites W1971023808 @default.
• W2130992263 cites W2002181841 @default.
• W2130992263 cites W2014145760 @default.
• W2130992263 cites W2015917939 @default.
• W2130992263 cites W2019607817 @default.
• W2130992263 cites W2036199674 @default.
• W2130992263 cites W2037859708 @default.
• W2130992263 cites W2041109673 @default.
• W2130992263 cites W2046975261 @default.
• W2130992263 cites W2059039824 @default.
• W2130992263 cites W2084688538 @default.
• W2130992263 cites W2094599840 @default.
• W2130992263 cites W2111806598 @default.
• W2130992263 cites W2148643283 @default.
• W2130992263 cites W2148998801 @default.
• W2130992263 cites W2158479847 @default.
• W2130992263 cites W2167733127 @default.
• W2130992263 cites W2168108459 @default.
• W2130992263 cites W2169961966 @default.
• W2130992263 cites W2410040686 @default.
• W2130992263 doi "https://doi.org/10.1158/1078-0432.ccr-14-0489" @default.
• W2130992263 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25278449" @default.
• W2130992263 hasPublicationYear "2014" @default.
• W2130992263 type Work @default.
• W2130992263 sameAs 2130992263 @default.
• W2130992263 citedByCount "36" @default.
• W2130992263 countsByYear W21309922632015 @default.
• W2130992263 countsByYear W21309922632016 @default.
• W2130992263 countsByYear W21309922632017 @default.
• W2130992263 countsByYear W21309922632018 @default.
• W2130992263 countsByYear W21309922632019 @default.
• W2130992263 countsByYear W21309922632020 @default.
• W2130992263 countsByYear W21309922632021 @default.
• W2130992263 countsByYear W21309922632022 @default.
• W2130992263 countsByYear W21309922632023 @default.
• W2130992263 crossrefType "journal-article" @default.
• W2130992263 hasAuthorship W2130992263A5009732369 @default.
• W2130992263 hasAuthorship W2130992263A5020334875 @default.
• W2130992263 hasAuthorship W2130992263A5026186298 @default.
• W2130992263 hasAuthorship W2130992263A5031088617 @default.
• W2130992263 hasAuthorship W2130992263A5043871151 @default.
• W2130992263 hasAuthorship W2130992263A5047212274 @default.
• W2130992263 hasAuthorship W2130992263A5062167990 @default.
• W2130992263 hasAuthorship W2130992263A5063861158 @default.
• W2130992263 hasAuthorship W2130992263A5067387322 @default.
• W2130992263 hasAuthorship W2130992263A5079064470 @default.
• W2130992263 hasAuthorship W2130992263A5091696839 @default.
• W2130992263 hasBestOaLocation W21309922632 @default.
• W2130992263 hasConcept C121608353 @default.
• W2130992263 hasConcept C126322002 @default.
• W2130992263 hasConcept C2776694085 @default.
• W2130992263 hasConcept C2776817873 @default.
• W2130992263 hasConcept C2777511904 @default.
• W2130992263 hasConcept C2778575703 @default.
• W2130992263 hasConcept C2778894405 @default.
• W2130992263 hasConcept C2780192828 @default.
• W2130992263 hasConcept C2781303535 @default.
• W2130992263 hasConcept C502942594 @default.
• W2130992263 hasConcept C530470458 @default.
• W2130992263 hasConcept C71315377 @default.
• W2130992263 hasConcept C71924100 @default.
• W2130992263 hasConcept C98274493 @default.
• W2130992263 hasConceptScore W2130992263C121608353 @default.
• W2130992263 hasConceptScore W2130992263C126322002 @default.
• W2130992263 hasConceptScore W2130992263C2776694085 @default.
• W2130992263 hasConceptScore W2130992263C2776817873 @default.
• W2130992263 hasConceptScore W2130992263C2777511904 @default.
• W2130992263 hasConceptScore W2130992263C2778575703 @default.
• W2130992263 hasConceptScore W2130992263C2778894405 @default.
• W2130992263 hasConceptScore W2130992263C2780192828 @default.
• W2130992263 hasConceptScore W2130992263C2781303535 @default.
• W2130992263 hasConceptScore W2130992263C502942594 @default.
• W2130992263 hasConceptScore W2130992263C530470458 @default.
• W2130992263 hasConceptScore W2130992263C71315377 @default.
• W2130992263 hasConceptScore W2130992263C71924100 @default.
• W2130992263 hasConceptScore W2130992263C98274493 @default.
• W2130992263 hasIssue "24" @default.
• W2130992263 hasLocation W21309922631 @default.

• next